Provided by Tiger Trade Technology Pte. Ltd.

Immutep Limited

0.2877
-0.0292-9.21%
Post-market: 0.2849-0.0028-0.97%19:47 EDT
Volume:576.50K
Turnover:165.55K
Market Cap:42.35M
PE:-0.77
High:0.3104
Open:0.3104
Low:0.2800
Close:0.3169
52wk High:3.53
52wk Low:0.2800
Shares:147.19M
Float Shares:143.00M
Volume Ratio:0.63
T/O Rate:0.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3729
EPS(LYR):-0.3729
ROE:-77.31%
ROA:-42.45%
PB:0.97
PE(LYR):-0.77

Loading ...

Immutep Gets a New Bull at Jefferies

Dow Jones
·
Sep 15

Immutep provides update on development strategy for eftilagimod alfa

TIPRANKS
·
Sep 11

Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”)

GlobeNewswire
·
Sep 11

Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026

GlobeNewswire
·
Jul 24

Immutep Granted New US Patent for Cancer Treatment Methods

MT Newswires Live
·
Jul 14

Immutep granted new patent for eftilagimod alfa combination

TIPRANKS
·
Jul 14

Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor

GlobeNewswire
·
Jul 14

Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004

GlobeNewswire
·
Jul 13

Immutep Shares Rise After Maxim Group Upgrade

MT Newswires Live
·
Jun 18

Immutep Raised to Buy From Hold by Maxim Group

Dow Jones
·
Jun 17

Maxim Group Upgrades Immutep to Buy From Hold, $1.50 Price Target

MT Newswires Live
·
Jun 17

Immutep Ltd : Maxim Group Raises to Buy From Hold

THOMSON REUTERS
·
Jun 17

Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026

GlobeNewswire
·
Jun 04

Systemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer patients

GlobeNewswire
·
May 28

Immutep Hit With Securities Suit After TACTI-004 Trial Halt and 83% Stock Drop

TIPRANKS
·
May 22

Immutep Faces Securities Lawsuit After 83% Stock Collapse Following Phase III Trial Discontinuation

TIPRANKS
·
May 16

Largest borrow rate increases among liquid names

TIPRANKS
·
May 09

Immutep Receives Nasdaq Notice of Bid Price Deficiency

GlobeNewswire
·
Apr 30

Immutep Quarterly Activities Report Q3 FY26

GlobeNewswire
·
Apr 30

Immutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

GlobeNewswire
·
Apr 22